Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:
-- The first section of this topic is shown below --
- Acute, typically self-limited, febrile infection caused by orthomyxovirus influenza types A and B
- Marked by inflammation of nasal mucosa, pharynx, conjunctiva, and respiratory tract
- Outbreaks have varying degrees of severity and generally peak in winter.
- Influenza virus can undergo antigenic shift (abrupt change) leading to viral strains with little immunologic resistance in a population. This can result in pandemic outbreaks. Minor seasonal variations are called antigenic drift.
- System(s) affected: typical cases: head/eyes/ears/nose/throat; pulmonary; complicated cases: cardiac and CNS involvement
- Synonym(s): flu; grippe; acute catarrhal fever
- Predominant age: children (3 months to 16 years) and young adults
- Morbidity: seasonal morbidity and rates of hospitalization highest in very young (preschool), elderly (>75 years of age), and individuals with comorbid illness (lung disease, malignancy)
- Predominant sex: male = female
- Seasonal influenza in preuniversal vaccination: 95 million cases per year, typically fall/winter
- Attack rates in healthy children: 10–40% each year, prior to routine influenza vaccination
- Weekly reports: http://www.cdc.gov/flu/weekly
Etiology and Pathophysiology
Orthomyxovirus (influenza types A [majority] and B); influenza A virus subtypes HxNx based on hemagglutinin and neuraminidase
- Incubation is 1 to 4 days; infected persons are most contagious during peak symptoms.
- Spread by aerosolized droplets or contact with respiratory secretions
- Hemagglutinin binds to columnar respiratory epithelium where replication occurs, and neuraminidase protein facilitates spread along respiratory epithelium.
- For contracting disease
- Crowded environments such as nursing homes, barracks, schools, and correctional facilities
- For complications
- Neonates, infants, elderly
- Pregnancy, especially in 3rd trimester
- Chronic pulmonary diseases
- Cardiovascular diseases, including valvular problems and congestive heart failure (CHF)
- Metabolic disease, morbid obesity
- Malignancy; immunosuppression
- Neuromuscular diseases that limit respiratory function and ability to handle secretions
- Patients <19 years of age who are on long-term aspirin therapy
- Vaccination: All persons >6 months should be vaccinated annually unless contraindication present.
- Inactivated influenza vaccine (IIV) is available with either 3 (IIV3) or 4 (IIV4) strains of influenza. IIV also is available as high-dose, intradermal, cell culture-based (ccIV3), MF59-adjuvanted (aIIV3), and recombinant hemagglutinin vaccine (RIV3).
- Live attenuated influenza vaccine (LAIV) is an intranasal quadrivalent vaccine.
- IIV recommended annually for the following:
- All persons aged ≥6 months
- Vaccine should be administered annually as soon as the vaccine is available.
- Protection occurs 1 to 2 weeks after immunization.
- Typically mild side effects include low-grade fever and local reaction at vaccination site.
- Inactivated IM dose: ≥3 years of age: 0.5 mL; children 6 to 35 months of age: 0.25 mL
- Intradermal formulation for 18- to 64-year-olds uses a short 30-gauge needle in a single-use prefilled syringe with 0.1 mL vaccine; somewhat higher local reactions when given intradermal
- Single annual dose except for children <9 years of age, who should receive 2 doses (4 weeks apart) the first year they receive influenza vaccine.
- Vaccine contraindication: Severe allergy such as anaphylaxis to IIV components, hives from eggs are not considered a contraindication; observe all patients for 15 minutes after vaccination; no skin testing with influenza vaccine is needed in egg-allergic patients. RIV is safe in patients with an egg allergy.
- Precaution: Guillain-Barré syndrome within 6 weeks after a previous dose of influenza vaccine
- LAIV is not recommended for the 2017 to 2018 influenza season.
- IIV-HD: high-dose quadrivalent IIV
- Contains 4 times the antigen concentration of IIV
- Licensed for persons ≥65 years of age
- Results in higher antibody levels but somewhat higher rates of local reactions
- Advisory Committee on Immunization Practices does not express a preference for/against IIV-HD.
- Antiviral prophylaxis depends on current resistance patterns each year; see http://www.cdc.gov/flu/ for current patterns or check with local health department.
- In high-risk groups that have not been vaccinated or need additional control measures during epidemics; not a substitute for vaccination unless vaccine is contraindicated (1)[A]
- During influenza season, for those with contraindications to vaccine who have been exposed to the virus (1)[A]
- For staff and residents in nursing home outbreaks
- For immune-deficient persons who are expected not to respond to vaccination after viral exposure
- Vaccinate children 6 months and older annually.
- For prophylaxis, oseltamivir dosage varies by weight and is recommended by the CDC for prophylaxis for children ≥3 months; zanamivir is approved for prophylaxis for children ≥5 years of age at a dosage of 2 inhalations per day. Prophylaxis treatment duration is 7 days. For prophylaxis, the dosage of amantadine and of rimantadine is 5 mg/kg/day up to 150 mg in 2 divided doses. Currently, amantadine and rimantadine are not recommended due to resistance.
- The CDC recommends vaccinating all women who will be pregnant during influenza season.
- If unvaccinated at the time of flu season, pregnant women should receive IIV or RIV.
- Oseltamivir, zanamivir, peramivir, rimantadine, and amantadine are pregnancy Category C.
Commonly Associated Conditions